Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | TOP2A | P11388 | 3/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831159 | 0.80 | EGFR (0.53) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL15684787 | 0.79 | ESR1 (0.36) | EGFRTOP2ATOP2BPDE10A | |
| SCHEMBL27781219 | 0.79 | EGFR (0.51) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL22198990 | 0.77 | EGFR (0.50) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL681857 | 0.77 | EGFR (0.57) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL682003 | 0.77 | EGFR (0.50) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL2178320 | 0.77 | EGFR (0.53) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL12435442 | 0.76 | KMT2A (0.50) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL3204003 | 0.73 | EGFR (0.53) | EGFRTOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL12969936 | 0.73 | TLR8 (0.62) | KMT2AKDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261212-B1 | Preparation of quinoline-substituted carbamate derivatives | ABBVIE INC (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2409964-B1 | Process for the preparation of carbonate derivatives | ABBOTT LAB (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-1192139-B1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2409964-A2 | Preparation of substituted carbonate and carbamate derivatives | Abbott Laboratories (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2261212-A2 | Preparation of quinoline-substituted carbonate and carbamate derivatives | Abbott Laboratories (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2008081096-A2 | QUINOLINYL DERIVATIVES, METHOD FOR PREPARING SAME, PHARMACEUTIC COMPOSITIONS CONTAINING SAME, AND USE THEREOF AS HYPOGLYCEMIANT AND HYPOLIPEMIANT AGENTS | LES LABORATOIRES SERVIER (FR) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081096-A2 | QUINOLINYL DERIVATIVES, METHOD FOR PREPARING SAME, PHARMACEUTIC COMPOSITIONS CONTAINING SAME, AND USE THEREOF AS HYPOGLYCEMIANT AND HYPOLIPEMIANT AGENTS | LES LABORATOIRES SERVIER (FR) | 2008-07-10 | — | — | WO | disclosed |
| CN-100355734-C | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBOTT LAB (US) | 2007-12-19 | — | — | CN | disclosed |
| US-7074932-B2 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2006-07-11 | — | — | US | disclosed |
| US-20060128962-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ALLEN MICHAEL S | 2006-06-15 | — | — | US | disclosed |
| CN-1217934-C | Process for the preparation of quinoline-substituted carbonate and carbamate derivatives | ABBOTT LAB (US) | 2005-09-07 | — | — | CN | disclosed |
| CN-1663952-A | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBOTT LAB (US) | 2005-09-07 | — | — | CN | disclosed |
| US-20030199696-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-6579986-B2 | Metal-catalyzed coupling reactions for 6-o-substituted macrolide antibiotics | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| US-20020165390-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-11-07 | — | — | US | disclosed |
| CN-1370148-A | Process for the preparation of quinoline-substituted carbonate and carbamate derivatives | ABBOTT LAB (US) | 2002-09-18 | — | — | CN | disclosed |
| US-6417366-B2 | CHEMICAL INTERMEDIATE FOR MACROLACTONE ANTIBIOTIC | ABBOTT LABORATORIES | 2002-07-09 | — | — | US | disclosed |
| EP-1192139-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | Abbott Laboratories (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001000582-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128962-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | EGFR 3336/4885TOP2A 123/4885TOP2B 249/4885 |
| US-20030199696-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | EGFR 3336/4885TOP2A 123/4885TOP2B 249/4885 |
| US-20020165390-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | EGFR 3336/4885TOP2A 123/4885TOP2B 249/4885 |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | EGFR 3336/4885TOP2A 123/4885TOP2B 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.